# Zanamivir Versus Trivalent Split Virus Influenza Vaccine

> **NCT00784784** · PHASE3 · COMPLETED · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 64 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluviral
- **DRUG:** Zanamivir

## Key facts

- **NCT ID:** NCT00784784
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784784, "Zanamivir Versus Trivalent Split Virus Influenza Vaccine". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00784784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*